Recent Corporate Highlights

Conference and webcast information

Bio-Path Holdings will hold a conference call and webcast today at 8:30 a.m. ET to review those 2020s monetary effects and provide a general update on the company. To access the convention call, call (844) 815-4963 (national) or (210) 229-8838 (international) and see convention identification number 3237808. You will have a live call audio webcast and a webcast archived media segment of the company’s online page in www.biopathholdings.com.

About Bio-Path Holdings, Inc.

Bio-Path is a biogeneration company that emerges DNAbilize®, a new generation that has resulted in a pipe of ARNI NANOparticles that can be administered through an undeniable intravenous transfusion. Bio-Path’s main candidate product, prexigebersen (BP1001, targeted at the grb2 protein), is in a Phase 2 for blood cancers and prexigebersen-A, a pharmacological amendment to prexigebersen, is being studied through the FDA to initiate Phase 1 studies on counterfeit tumors. This is followed by BP1002, aimed at the Bcl-2 protein, where it will be evaluated in clinical studies of counterfeit lymphomas and tumors.

Forward-looking statements

This press release includes forward-looking statements made in accordance with the provisions of the port rule of federal securities laws. These statements are based on the existing expectations of the administration and are therefore subject to uncertainty and adjustments in the circumstances. Any explicit or implied statements contained in this press release other than statements of old facts could possibly be considered forward-looking statements. All statements that are not old facts contained in this press release are forward-looking statements involving dangers and uncertainties, adding the impact, dangers and uncertainties related to COVID-19 and movements taken through the government or other government in connection with it, Bio- Path’s ability to raise the additional capital required in a timely manner in order to continue his activities Organize a successful clinical progression of his technologies , the time of recording and publication of knowledge in these clinical studies and the accuracy of such knowledge, limited populations of patients from the first years of life. early-stage clinical trials and the option that the effects of more complex clinical trials with much larger patient populations may not be consistent with the Early Stage Clinical Trials Array and other known hazards in bio-Path’s most recent annual report on Form 10-K, throughout the next quarter reports on Form 10-Q and other reports that Bio-Path presents with the values and Ex replaces the Commission Ion from time to time. These documents must be obtained upon request from Bio-Path Holdings or at www.sec.gov. Bio-Path rejects any legal objective or responsibility to update or revise any forward-looking statements, whether as a result of new information, long-term occasions or otherwise.

Contact Information:

Investors